. Author manuscript; available in PMC: 2021 Aug 4.

Published in final edited form as: Nat Biomed Eng. 2020 Dec;4(12):1128–1133. doi: 10.1038/s41551-020-00658-w

Table 1 |.

Leading SARS-CoV-2 vaccine candidates supported by Operation Warp Speed in the United States.

Vaccine	Technology platform	Developers	Development status and clinical-trial number
mRNA-1273²⁴	mRNA	Moderna Therapeutics & NIAID	Phase 3 NCT04470427
BNT162b2²⁵	mRNA	BioNTech RNA Pharmaceuticals & Pfizer	Phase 3 NCT04368728
AZD1222²⁶	Adenovirus vaccine	University of Oxford & AstraZeneca	Phase 3 NCT04516746
Ad26.COV2-S	Adenovirus vaccine	Johnson & Johnson	Phase 3 NCT04505722
-	VSV and measles-based	Merck Sharp & Dohme Corp.	Phase 1/2 NCT04498247